New insider activity at Joint ( (JYNT) ) has taken place on August 19, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Christopher M Grandpre has made a significant investment in Joint by purchasing 24,388 shares of the company’s stock, amounting to a total value of $263,297.
Recent Updates on JYNT stock
In the past 24 hours, Joint Corp (JYNT) has experienced notable developments following its Q2 earnings call and subsequent announcements. The company reported a 5% revenue increase and a shift from a net loss to a profit, alongside a 52% rise in adjusted EBITDA. Strategic moves included refranchising 37 clinics and launching a mobile app to boost patient engagement. However, Joint Corp revised its 2025 guidance downward due to macroeconomic headwinds and challenges in new patient acquisition, lowering sales expectations but raising EBITDA guidance, reflecting effective cost management. Additionally, the company announced a delay in filing its Form 10-Q due to material errors in previous financial statements, necessitating restatements. Despite these challenges, the appointment of a new CFO and a strong cash position provide a foundation for future growth, though technical indicators suggest bearish momentum impacting short-term performance.
Spark’s Take on JYNT Stock
According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including consistent net losses and cash flow sustainability issues. While technical indicators suggest bearish momentum, recent corporate events and earnings call insights provide some optimism with strategic shifts and improved EBITDA.
To see Spark’s full report on JYNT stock, click here.
More about Joint
YTD Price Performance: 1.15%
Average Trading Volume: 64,123
Technical Sentiment Signal: Strong Sell
Current Market Cap: $167.1M